Lacosamide is a novel antiepileptic drug and is a member of a family of functionalized amino acids, more specifically, analogues of the endogenous amino acid and NMDA-receptor modulator D-serine. Various animal and human study shown that LCM have Antinociceptive efficacy, adjuvant analgesics efficacy and safety in cancer pain management¬¬, anti hyperalgesic efficacy, and successful treatment in childhood prolonged refractory status epilepticus, nonconvulsive status epilepticus after failure of first line therapy, in diabetic neuropathic pain. The LCM may be used for the treatment or prophylaxis of migraine, fibromyalgia syndrome, osteoarthritis, post herpetic neuralgia. LCM is a white to light yellow crystalline powder with a chiral purity of (R)-enantiomer and is a weak base. LCM is a BCS Class I substance and soluble in 2-propanol, ethanol, DMSO, Dimethylformamide and sparingly soluble in water and is not a hygroscopic. Commercial synthesis process comprises five steps and (R)--N-benzyl-2-(benzyloxy carbonylamino)-3-methoxypropionamide is an intermediate useful for preparing LCM. LCM are very stable at elevated temperature and high humidity. Under strong acidic condition pH 1 and alkaline condition pH 10 at a temperature of 60°C the substance rapidly decomposed. Moderate degradation reported after addition of 3% hydrogen peroxide to aqueous solution of pH 3, pH7, pH 10. Few HPLC methods are reported for LCM estimation in human’s and animal’s plasma, saliva and serum and in bulk and its formulation. LCM is avilable as film coated tablet, oral solution and solution for intravenous infusion forms in USA, Europe, Australia and in India
Loading....